鼻咽癌患者血清抗EB病毒潜伏膜蛋白2A抗体的检测及其临床意义  

Detection and clinical significance of anti-EBV-LMP2A antibody in patients with nasopharyngeal carcinoma

作　　者：马俊[1] 张大为[1] 伍丽娟[1] 严仁纯 吴礼锋[1] 刘少峰[1] 

机构地区：[1]皖南医学院附属弋矶山医院耳鼻咽喉头颈外科

出　　处：《中国临床药理学与治疗学》2016年第8期890-893,共4页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：皖南医学院中青年科研基金项目(WK2014F04)

摘　　要：目的:检测鼻咽癌患者血清抗EB病毒潜伏膜蛋白2A抗体并探讨其临床意义。方法:以重组质粒p ET28a表达的EB病毒潜伏膜蛋白2A重组表位蛋白为检测抗原,ELISA和Western blot检测正常人和鼻咽癌患者血清抗EBV-LMP2A抗体。结果:ELISA检测鼻咽癌患者和正常人血清抗EBV-LMP2A抗体水平分别为0.966±0.127、0.425±0.103,两组比较差异具有统计学意义(P<0.01);Western blot检测二者的抗体水平比较差异具有统计学意义(P<0.01)。结论:鼻咽癌患者血清EBV-LMP2A抗体表达显著高于正常对照,可能与鼻咽癌的发生有关,可作为鼻咽癌的辅助诊断指标。AIM： To detect the serum EpstainBarr virus（ EBV） latent membrane protein 2A（ LMP2A） antibody in patients with nasopharyngeal carcinoma and to appraise its clinical significance.METHODS： Healthy volunteers and patients with nasopharyngeal carcinoma were detected by ELISA and Western blot for serum EBV-LMP2 A antibody,which was expressed by recombinant plasmid p ET28 a. RESULTS： The average levels of serum anti-EBV-LMP2 A antibody displayed by absorbance of ELISA in nasopharyngeal carcinoma group and control group were significantly different（ 0. 966 ±0. 127） vs（ 0. 425 ± 0. 103）（ P〈0. 01）. Western blot also showed the same changes. CONCLUSION： The serum EBV-LMP2 A antibody of nasopharyngeal carcinoma patients was significantly higher than the control group. It may be associated with nasopharyngeal carcinoma,which can be used as diagnostic indicator of nasopharyngeal carcinoma.

关 键 词：鼻咽癌 Epstain-Barr病毒 潜伏膜蛋白2A 抗体 检测 

分 类 号：R965.2[医药卫生—药理学]